论文部分内容阅读
肾移植患者大约５０～８０％存在脂代谢异常，其病因与多种因素有关，其中强的松最为证据确凿，ＣｓＡ也可能与高脂血症关系密切。肾移植术后的高脂血症类型由术前的高甘油三酯血症为主转为以高胆固醇血症为主。现发现高脂血症是肾移植术后心血管疾病发病的主要危险因素，而且许多实验及临床证据证明高脂血症能加速慢性排斥进程，作用机制可能通过被氧化修饰的低密度脂蛋白（ＯＭＬＤＬ）完成；ＯＭＬＤＬ能激活Ｔ细胞，上调粘附分子及Ⅱ类ＭＨＣ抗原表达形成一系列免疫反应。３－羟基－３－甲基戊二醛辅酶Ａ还原酶抑制剂用于此类患者较为理想，具有降低血脂及协同免疫抑制双重作用。
About 50-80% of renal transplant patients have dyslipidemia, the etiology and a variety of factors, including the most evidence of prednisone, CsA may also be closely related with hyperlipidemia. The type of hyperlipidemia after renal transplantation was changed from preoperative hypertriglyceridemia to hypercholesterolemia. It is found that hyperlipidemia is the main risk factor for cardiovascular disease after renal transplantation, and many experimental and clinical evidence that hyperlipidemia can accelerate the process of chronic rejection, the mechanism may be oxidized by the modified low-density lipoprotein ( OMLDL); OMLDL can activate T cells, up-regulate the expression of adhesion molecules and MHC class II antigen to form a series of immune responses. 3-hydroxy-3-methyl-glutaraldehyde coenzyme A reductase inhibitor is ideal for such patients, with the dual role of lowering blood fat and synergistic immunosuppression.